This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wikstrand, C. J. Articles by Bigner, D. D. Search for Related Content PubMed PubMed Citation Articles by Wikstrand, C. J. Articles by Bigner, D. D.

Surface Antigenic Characteristics of Human Glial Brain Tumor Cells¹

Departments of Pathology and Surgery, Duke University Medical Center, Durham, North Carolina 27710 [C. J. W., D. D. B.], and Division of Neurosurgery, North Carolina Memorial Hospital, The University of North Carolina, Chapel Hill, North Carolina 27514 [M. S. M.]

The surface antigenic characteristics of human glial brain tumor (HGBT) cells were studied by complement-dependent cytotoxic antibody assays and indirect membrane immunofluorescence. Eight permanent, well-characterized cell lines derived from human gliomas were used for analysis with antisera raised by hyperimmunization of nonhuman primates (Macaca fascicularis) with glioblastoma multiforme tissue or established HGBT cell lines. Exhaustive absorption of these antisera to remove predominantly antispecies activity rendered HLA nonreactive "preabsorbed" antisera, which reacted with a large panel of gliomatous and nongliomatous human tumor cells: 1 carcinoma, 2 sarcomas, 2 melanomas, 1 neuroblastoma, and 8 HGBT cell lines. Four lymphoblastoid lines and 2 carcinomas were unreactive. After further absorption with a human osteogenic sarcoma cell line, the antisera demonstrated significant levels of reactivity for 8 tested HGBT cell lines and no longer reacted with the nongliomatous cultured tumor cell lines. Therefore, extensive absorption of nonhuman primate anti-human glioma sera removed all activity for the nongliomatous cell lines tested, but it left significant reactivity against a glial tumor cell line-associated antigen(s) present on all 8 human glioma cell lines tested.

¹ This investigation was supported in part by USPHS Grants CA-11898 and CA-22790 from the National Cancer Institute.

² Fellow of the Leukemia Society of America, Inc. To whom requests for reprints should be addressed.

³ Recipient of National Institute of Neurological and Communicative Diseases and Stroke Teacher-Investigator Award 1F11NS11063-02 and Junior Faculty Clinical Fellowship 257B from the American Cancer Society.

Received 5/ 6/77. Accepted 8/ 3/77.